The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance
1997

Idoxifene's Effect on Breast Cancer Growth

Sample size: 94 publication Evidence: moderate

Author Information

Author(s): SRD Johnston, S Riddler, BP Haynes, R A'Hern, IE Smith, M Jarman, M Dowsett

Primary Institution: Royal Marsden Hospital

Hypothesis

Does idoxifene inhibit the growth of MCF-7 breast cancer xenografts and reduce acquired anti-oestrogen resistance compared to tamoxifen?

Conclusion

Idoxifene is more effective than tamoxifen in inhibiting the growth of MCF-7 breast cancer xenografts and may reduce the development of acquired resistance.

Supporting Evidence

  • Idoxifene treatment resulted in significantly lower tumor volumes compared to tamoxifen.
  • None of the tumors treated with idoxifene developed acquired resistance during the study period.
  • Idoxifene was more effective than tamoxifen at inhibiting MCF-7 cell growth.

Takeaway

Idoxifene helps stop breast cancer from growing better than tamoxifen and might help prevent the cancer from becoming resistant to treatment.

Methodology

The study involved establishing MCF-7 breast cancer xenografts in mice and comparing the effects of idoxifene and tamoxifen on tumor growth over six months.

Limitations

The study was conducted in a mouse model, which may not fully replicate human responses.

Participant Demographics

Ovariectomized athymic nude mice were used in the study.

Statistical Information

P-Value

0.01

Statistical Significance

p=0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication